Annovis Bio Stock Net Income
ANVS Stock | USD 6.71 0.17 2.60% |
Annovis Bio fundamentals help investors to digest information that contributes to Annovis Bio's financial success or failures. It also enables traders to predict the movement of Annovis Stock. The fundamental analysis module provides a way to measure Annovis Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annovis Bio stock.
Last Reported | Projected for Next Year | ||
Net Loss | -41.7 M | -39.6 M | |
Net Loss | -13 M | -12.4 M | |
Net Loss | -56.2 M | -53.4 M | |
Net Loss | (6.23) | (5.92) | |
Net Income Per E B T | 0.89 | 0.62 |
Annovis | Net Income |
Annovis Bio Company Net Income Analysis
Annovis Bio's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Annovis Bio Net Income | (56.2 M) |
Most of Annovis Bio's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annovis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Annovis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Annovis Bio is extremely important. It helps to project a fair market value of Annovis Stock properly, considering its historical fundamentals such as Net Income. Since Annovis Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Annovis Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Annovis Bio's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Based on the recorded statements, Annovis Bio reported net income of (56.2 Million). This is 116.47% lower than that of the Biotechnology sector and 180.24% lower than that of the Health Care industry. The net income for all United States stocks is 109.84% higher than that of the company.
Annovis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annovis Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annovis Bio could also be used in its relative valuation, which is a method of valuing Annovis Bio by comparing valuation metrics of similar companies.Annovis Bio is currently under evaluation in net income category among its peers.
Annovis Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Annovis Bio from analyzing Annovis Bio's financial statements. These drivers represent accounts that assess Annovis Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Annovis Bio's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 43.2M | 47.6M | 134.1M | 109.6M | 98.7M | 55.8M | |
Enterprise Value | 43.6M | 39.5M | 88.4M | 81.2M | 73.1M | 44.9M |
Annovis Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Annovis Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Annovis Bio's managers, analysts, and investors.Environmental | Governance | Social |
Annovis Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Annovis Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Annovis Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Annovis Bio's value.Shares | D. E. Shaw & Co Lp | 2024-09-30 | 24.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 22.1 K | Northern Trust Corp | 2024-09-30 | 21.9 K | Spears Abacus Advisors Llc | 2024-09-30 | 20 K | Bank Of New York Mellon Corp | 2024-09-30 | 19.1 K | Greenwich Wealth Management Llc | 2024-09-30 | 16.5 K | Bank Of Montreal | 2024-09-30 | 13.5 K | Bmo Capital Markets Corp. | 2024-09-30 | 13.5 K | Lokken Investment Group Llc | 2024-09-30 | 12.2 K | Vanguard Group Inc | 2024-09-30 | 380.3 K | Citadel Advisors Llc | 2024-09-30 | 102.7 K |
Annovis Fundamentals
Return On Equity | -5.97 | ||||
Return On Asset | -1.55 | ||||
Current Valuation | 79.94 M | ||||
Shares Outstanding | 13.8 M | ||||
Shares Owned By Insiders | 20.40 % | ||||
Shares Owned By Institutions | 8.83 % | ||||
Number Of Shares Shorted | 1.39 M | ||||
Price To Earning | (0.43) X | ||||
Price To Book | 13.11 X | ||||
EBITDA | (45.04 M) | ||||
Net Income | (56.2 M) | ||||
Cash And Equivalents | 35.97 M | ||||
Cash Per Share | 4.41 X | ||||
Total Debt | 17.96 M | ||||
Debt To Equity | (0.31) % | ||||
Current Ratio | 28.11 X | ||||
Book Value Per Share | 0.53 X | ||||
Cash Flow From Operations | (39.97 M) | ||||
Short Ratio | 4.02 X | ||||
Earnings Per Share | (4.22) X | ||||
Target Price | 34.8 | ||||
Beta | 1.7 | ||||
Market Capitalization | 92.58 M | ||||
Total Asset | 10.21 M | ||||
Retained Earnings | (110.26 M) | ||||
Working Capital | 5.93 M | ||||
Current Asset | 986 K | ||||
Current Liabilities | 216 K | ||||
Net Asset | 10.21 M |
About Annovis Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annovis Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annovis Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annovis Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.